secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001619856-23-000134
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou reaches FDA alignment on CB-010 phase 3 trial design; CMO to depart Dec 31
--------------------------------------------------------------------------------

- FDA accepts comparator arm of platinum-based immunochemotherapy + HDCT + ASCT for CB-010 phase 3 in 2L r/r LBCL.
- Phase 3 pivotal trial initiation planned by year-end 2024; RP2D and initial dose expansion data expected Q2 2024.
- CB-010 is first allogeneic anti-CD19 CAR-T in 2L LBCL; granted RMAT, Fast Track, and Orphan Drug designations.
- Chief Medical Officer Syed Rizvi to leave effective Dec 31, 2023; separation agreement with release required.
- Search underway for new CMO; ANTLER dose expansion enrollment continues with 22 U.S. sites and 1 in Australia active.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000134/0001619856-23-000134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000134/crbu-20231211.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer